Invita D3®Colecalciferol 25,000unit per 1ml oral solution Invita D3®Colecalciferol 50,000unit per 1ml oral solution
Plenachol®(Colecalciferol )
Formulary
HIGH DOSE BOOST
Plenachol®Colecalciferol 20,000unit capsules
Stexerol D3®(Colecalciferol )
Formulary
HIGH DOSE BOOST
Stexerol D3®Colecalciferol 25,000unit tablets
Thorens®(Colecalciferol )
Formulary
Maintenance dose (without calcium)
Thorens®Colecalciferol 10,000unit/ml drops (1 drop ≡ 200unit Colecalciferol)
Desunin®(Colecalciferol )
Formulary
Maintenance dose (without calcium)
Desunin®Colecalciferol 400unit tablets
Fultium D3®(Colecalciferol )
Formulary
Maintenance dose (without calcium)
Fultium D3®Colecalciferol 800unit capsules
Accrete D3®(Colecalciferol and calcium carbonate)
Formulary
Maintenance dose (with calcium)
Colecalciferol 10microgram (equivalent to 400unit of vitamin D3) plus Calcium carbonate 1500mg (equivalent to 600mg of elemental calcium) tablets
Reserve for patients that cannot tolerate chewable tablets
Adcal-D3®(Colecalciferol and calcium carbonate)
Formulary
Maintenance dose (with calcium)
Colecalciferol 5microgram (equivalent to 200unit of vitamin D3) plus Calcium carbonate 750mg (equivalent to 300mg of elemental calcium) caplets
Adcal-D3®(Colecalciferol and calcium carbonate)
Formulary
Maintenance dose (with calcium)
Colecalciferol 10microgram (equivalent to 400unit of vitamin D3) plus Calcium carbonate 1500mg (equivalent to 600mg of elemental calcium) chewable tablets
Calceos®(Colecalciferol and calcium carbonate)
Formulary
Maintenance dose (with calcium)
Colecalciferol 10microgram (equivalent to 400unit of vitamin D3) plus Calcium carbonate 1250mg (equivalent to 500mg of elemental calcium) chewable tablets
....
Key
Notes
Section Title (top level)
Section Title (sub level)
First Choice item
Non Formulary section
Restricted Drug
Unlicensed
Display tracking information
Link to adult BNF
Link to children's BNF
Link to SPCs
Scottish Medicines Consortium
Cytotoxic Drug
Controlled Drug
High Cost Medicine
Cancer Drugs Fund
NHS England
Homecare
CCG
High Cost Drug Approval System
Traffic Light Status Information
Status
Description
Medicines that can only be prescribed within Secondary Care.
Examples of medicines which fall into this category are:
Certain new medicines and new indications for older medicines where there is at present
no experience of use in Primary Care.
Medicines or dressings not available or prescribable in Primary Care.
Where a medicine has been classified as Amber E, but an approved shared-care guideline is not yet available
Medicines which can be prescribed within Secondary Care, but are only suitable for prescribing in Primary Care after specialist referral. There is no need for approved shared care guidelines for medicines in this category. This replaces Amber 2 on the North Staffs Formulary.
Medicines which can be prescribed within Secondary Care, but are only considered suitable for prescribing in Primary Care under an approved shared-care agreement (ESCA) or Rationale for Initiation, Continuation and Discontinuation (RICaD). This replaces Amber 1 on the North Staffs Formulary
Medicines which can be prescribed in either Primary or Secondary Care.
These medicines have been reviewed by the New Medicines Committee and the Area Prescribing Committee and found not to be suitable for inclusion in the Joint Formulary.
Inadequate or weak evidence for efficacy
No clearly defined local need
Lack of long term safety data
No perceived benefit over established formulary alternatives
Prescribers can consider these medicines where formulary alternatives are unsuitable, ineffective or
not tolerated.
